Daré Bioscience (NASDAQ:DARE) Shares Cross Above 50 Day Moving Average of $0.33

Shares of Daré Bioscience, Inc. (NASDAQ:DAREGet Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.33 and traded as high as $0.37. Daré Bioscience shares last traded at $0.36, with a volume of 270,546 shares changing hands.

Analyst Ratings Changes

Several analysts have issued reports on DARE shares. Dawson James cut Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th. HC Wainwright dropped their price objective on shares of Daré Bioscience from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, November 10th.

Read Our Latest Stock Analysis on DARE

Daré Bioscience Stock Performance

The firm has a market cap of $35.68 million, a PE ratio of -0.77 and a beta of 1.03. The firm’s 50 day moving average price is $0.33 and its two-hundred day moving average price is $0.45.

Hedge Funds Weigh In On Daré Bioscience

A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new position in Daré Bioscience during the first quarter worth about $34,000. Citigroup Inc. purchased a new position in Daré Bioscience during the first quarter worth about $40,000. BlackRock Inc. boosted its position in shares of Daré Bioscience by 63.7% during the 1st quarter. BlackRock Inc. now owns 602,036 shares of the biotechnology company’s stock worth $897,000 after purchasing an additional 234,243 shares during the period. Vanguard Group Inc. boosted its position in shares of Daré Bioscience by 13.0% during the 1st quarter. Vanguard Group Inc. now owns 3,453,021 shares of the biotechnology company’s stock worth $5,145,000 after purchasing an additional 396,968 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Daré Bioscience during the 1st quarter worth approximately $150,000. 7.41% of the stock is currently owned by hedge funds and other institutional investors.

About Daré Bioscience

(Get Free Report)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.

Read More

Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.